How do Cardizem (diltiazem) and Cardene (diltiazem) differ in formulation, dosing schedule, and clinical use?

Cardizem vs Cardene: Key Differences

Cardizem (diltiazem) and Cardene (nicardipine) are both calcium channel blockers, but they differ fundamentally in their chemical class, clinical applications, and dosing schedules—diltiazem is a non-dihydropyridine with rate-controlling properties used for arrhythmias and hypertension, while nicardipine is a dihydropyridine primarily used for hypertension without significant rate control effects.

Chemical Classification and Mechanism

Diltiazem (Cardizem) is a non-dihydropyridine calcium channel blocker that blocks L-type calcium channels in both cardiac and vascular smooth muscle. It produces significant effects on the SA and AV nodes, slowing heart rate and AV nodal conduction while also causing peripheral vasodilation 1.

Nicardipine (Cardene) is a dihydropyridine calcium channel blocker with predominantly peripheral arterial vasodilatory effects and minimal to no effects on SA or AV nodal conduction 2, 3. This fundamental difference drives their distinct clinical applications.

Formulations and Dosing Schedules

Cardizem (Diltiazem)

Oral formulations 4:

• Immediate release: 30-90 mg four times daily (short duration of action)
• Sustained release (SR): 120-360 mg once daily (long duration of action)
• Extended release (CD): 180-540 mg once daily for hypertension; 120-480 mg once daily for angina

Intravenous formulation 1:

• Initial bolus: 0.25 mg/kg (15-20 mg) IV over 2 minutes
• Repeat bolus: 0.35 mg/kg (20-25 mg) IV after 15 minutes if needed
• Maintenance infusion: 5-15 mg/hour, titrated to heart rate

Cardene (Nicardipine)

Oral formulations 2, 5:

• Immediate release: 20-40 mg three times daily (short duration of action)
• Sustained release (SR): 30-60 mg twice daily

Intravenous formulation:

• Used primarily for hypertensive emergencies
• Continuous infusion with titration based on blood pressure response

Clinical Applications

Diltiazem (Cardizem) - Primary Uses

1. Supraventricular Tachycardia (SVT) and Atrial Fibrillation

Diltiazem is a first-line agent for acute rate control in hemodynamically stable patients with narrow-complex tachycardias 1, 6. IV diltiazem converts SVT to normal sinus rhythm in 64-98% of patients 6. For atrial fibrillation with rapid ventricular response, diltiazem achieves rate control more effectively than metoprolol, with 55% achieving target heart rate at 30 minutes and greater heart rate reductions (33 bpm vs 20 bpm) 7, 8.

2. Hypertension

For chronic hypertension management, diltiazem CD 180-360 mg once daily provides effective 24-hour blood pressure control 4, 9, 10. The once-daily CD formulation maintains normal circadian blood pressure patterns and significantly decreases the early morning blood pressure surge 9.

3. Angina Pectoris

Diltiazem reduces myocardial oxygen demand through decreased afterload, contractility, and heart rate while improving coronary blood flow 2, 3. In unstable angina/NSTEMI, diltiazem reduced reinfarction and refractory angina at 14 days without increasing mortality 2, 3.

4. Hypertrophic Cardiomyopathy

Diltiazem is a reasonable alternative to beta-blockers for symptomatic relief in obstructive HCM, providing negative inotropic and chronotropic effects 11.

Nicardipine (Cardene) - Primary Uses

1. Hypertension

Nicardipine SR 30-60 mg twice daily is effective for chronic hypertension management 5. The immediate-release formulation requires three-times-daily dosing due to its short duration of action 2.

2. Specific Arrhythmia Contexts

Nicardipine has limited utility in idiopathic ventricular tachycardia from the right ventricular outflow tract or left ventricle, but this is not a primary indication 2.

Critical Safety Considerations

When to AVOID Diltiazem

Absolute contraindications 1, 11:

• AV block greater than first degree (without pacemaker)
• Severe sinus node dysfunction (without pacemaker)
• Decompensated systolic heart failure or severe LV dysfunction
• Cardiogenic shock
• Wolff-Parkinson-White syndrome with atrial fibrillation/flutter
• Hypotension

Important caveat: Recent evidence suggests diltiazem use in heart failure with reduced ejection fraction (EF ≤40%) results in increased clinical deterioration, including greater need for inotropes, vasopressors, and ICU transfer (33% vs 21%, p=0.044) 12. This reinforces guideline recommendations to avoid diltiazem in HFrEF patients.

When to AVOID Nicardipine

Contraindications 2:

• Advanced aortic stenosis (due to afterload reduction)
• Unstable angina or acute MI without concomitant beta-blockade (rapid-release dihydropyridines cause reflex tachycardia)

Critical distinction: Unlike diltiazem, immediate-release nifedipine (another dihydropyridine) must be avoided in unstable angina/NSTEMI without beta-blockade due to increased adverse events from reflex sympathetic activation 2, 3. While nicardipine is better tolerated than immediate-release nifedipine, caution is still warranted.

Drug Interactions

Diltiazem 1:

• Major CYP3A4 substrate and moderate CYP3A4 inhibitor
• Increases levels of: simvastatin, cyclosporine, apixaban, rivaroxaban, digoxin (via P-glycoprotein inhibition)
• Avoid combining with other AV nodal blocking agents (risk of profound bradycardia)

Nicardipine:

• Fewer significant drug interactions than diltiazem
• Can be safely combined with beta-blockers and thiazide diuretics 5

Comparative Pharmacokinetics

Diltiazem formulations show significant variability 13, 14, 15:

• Cardizem SR vs CD: At steady state, CD provides more consistent plasma levels with less fluctuation (Cmax/Cmin ratio 3.2 vs 4.9) 14
• Single-dose Cardizem CD produces 46% higher Cmax than some formulations, but steady-state levels are similar 14
• Time to peak concentration varies: immediate-release 2.9 hours vs sustained-release 6.8 hours 15

Nicardipine SR requires twice-daily dosing, and total daily dose of immediate-release nicardipine is not a reliable guide for SR dosing—patients must be retitrated 5.

Practical Prescribing Algorithm

For acute rate control in SVT/atrial fibrillation with RVR:

1. Confirm hemodynamic stability and absence of contraindications (especially HFrEF, AV block, WPW)
2. Choose diltiazem: 0.25 mg/kg IV bolus over 2 minutes
3. If inadequate response at 15 minutes: give 0.35 mg/kg IV bolus
4. Start maintenance infusion 5-15 mg/hour if needed
5. Do NOT use nicardipine for this indication

For chronic hypertension without arrhythmia:

1. If rate control is needed (e.g., concurrent atrial fibrillation): Choose diltiazem CD 180-240 mg once daily
2. If pure vasodilation is desired without rate effects: Choose nicardipine SR 30 mg twice daily
3. Titrate based on blood pressure response measured 2-4 hours post-dose and at trough

For angina pectoris:

1. Choose diltiazem CD 120-180 mg once daily (first-line among calcium channel blockers)
2. Titrate up to 480 mg daily over 7-14 days if needed
3. Nicardipine is not indicated for angina

For hypertrophic cardiomyopathy:

1. If beta-blockers are contraindicated or ineffective: Choose diltiazem 120-360 mg daily
2. Avoid dihydropyridines like nicardipine (pure vasodilators worsen outflow obstruction) 11

Common Pitfalls

1. Using diltiazem in HFrEF: Despite its effectiveness for rate control, diltiazem causes clinical deterioration in patients with EF ≤40% 12. Use beta-blockers or digoxin instead.

2. Underdosing diltiazem in obesity: Recent evidence shows obese patients receive lower weight-based doses (0.16 mg/kg vs 0.21 mg/kg), yet higher initial doses increase rate control success without increasing adverse events 16. Consider ideal body weight dosing in obesity.

3. Combining diltiazem with beta-blockers acutely: The longer half-life of both agents means their effects overlap, risking profound bradycardia 17. If sequential use is needed, adenosine's short half-life makes it safer to give first, followed by diltiazem or beta-blocker.

4. Assuming bioequivalence between diltiazem formulations: Different sustained-release formulations have significantly different pharmacokinetic profiles 13, 14. When switching formulations, monitor clinical response rather than assuming dose equivalence.

5. Using nicardipine for rate control: Nicardipine lacks significant AV nodal blocking effects and is ineffective for controlling ventricular rate in atrial fibrillation 2.